ANGIOMAX Reduced Cardiac Mortality By 43 Percent And Improved Overall Survival By 31 Percent In Horizons-AMI Trial

The Medicines Company (NASDAQ: MDCO) today announced one-year follow-up data from the landmark HORIZONS-AMI trial demonstrated that Angiomax_ (bivalirudin) significantly reduced cardiac-related death by 43 percent (p=0.005), improved overall survival by 31 percent (p=0.029) and reduced major bleeding complications by 39 percent (p